GlassScriptPhysician profile
Jamie S Evans
NPI 1508800707
$1,193.04
in general payments reported to CMS, 2019-2025
15 companies · $46.03 in 2025
The $46.03 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $325 · 2021: $283 · 2022: $43.25 · 2023: $76.25 · 2024: $123 · 2025: $46.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $244.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $212.62 | 2019-2024 | Ozempic, Rybelsus |
| Pfizer INC. | $148.10 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $143.91 | 2020-2024 | Farxiga |
| Lilly USA, LLC | $136.14 | 2019-2025 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $113.51 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.92 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $82.07 | 2020-2021 | |
| Glaxosmithkline, LLC. | $76.02 | 2019-2023 | Trelegy Ellipta |
| Indivior INC. | $58.09 | 2019 | |
| Janssen Pharmaceuticals, INC | $57.37 | 2020-2021 | |
| Amgen INC. | $20.40 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.18 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.77 | 2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $13.46 | 2019 | |
| Abbvie INC. | $12.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.